C92.42 Acute promyelocytic leukemia, in relapse

Name of the Condition

• Acute Promyelocytic Leukemia, in Relapse

Summary

Acute Promyelocytic Leukemia (APL) in relapse is a recurrence of the disease after a period of remission, characterized by the return of abnormal promyelocytes in the bone marrow or blood. This state indicates that the leukemia has reactivated, requiring prompt intervention to manage the disease and prevent complications. Relapse may occur despite initial treatment response, and the condition retains the genetic and clinical features of APL, including the risk of severe bleeding.

Causes

The underlying cause of Acute Promyelocytic Leukemia is a genetic translocation between chromosomes 15 and 17, resulting in the PML-RARA fusion gene. In relapse, this genetic abnormality persists, driving the reemergence of leukemic cells. The exact triggers for relapse are not fully understood, but factors such as incomplete eradication of the fusion gene during initial treatment or acquired resistance to therapy may contribute.

Risk Factors

• Prior diagnosis of APL, as relapse is specific to this condition.
• Inadequate or incomplete initial treatment response.
• Presence of residual disease at the end of initial therapy.
• Genetic mutations that confer resistance to standard therapies.

Symptoms

• Return of symptoms associated with active APL, such as easy bruising, unexplained bleeding, or fatigue.
• Fever, infection, or other signs of bone marrow failure.
• Recurrence of abnormal promyelocytes in blood or bone marrow tests.

Diagnosis

Diagnosis of relapse is confirmed through blood tests showing elevated white blood cell counts or the presence of promyelocytes, along with bone marrow biopsy to detect leukemic cells. Genetic testing may identify the PML-RARA fusion gene, confirming the relapse. Imaging or other tests may be used to assess organ involvement or complications.

Treatment Options

• Reintroduction of targeted therapies, such as all-trans retinoic acid (ATRA) or arsenic trioxide, often combined with chemotherapy.
• Consideration of alternative regimens if prior treatments were ineffective or if resistance is suspected.
• Supportive care to manage bleeding, infection, or other complications.

Prognosis and Follow-Up

Prognosis in relapse depends on factors like the timing of relapse, prior treatment response, and the ability to achieve a second remission. Close monitoring, including regular blood and bone marrow tests, is essential to detect further relapse or treatment resistance. Long-term follow-up may be required to assess durability of response and manage late effects.

Complications

• Severe bleeding due to disseminated intravascular coagulation (DIC).
• Infection from bone marrow suppression.
• Organ damage from leukemic infiltration or treatment toxicity.
• Resistance to therapy, complicating future treatment options.

Lifestyle & Prevention

• Adherence to prescribed treatments and follow-up appointments.
• Prompt reporting of new or worsening symptoms to healthcare providers.
• Avoidance of known triggers, such as infections or exposure to toxins, where possible.

When to Seek Professional Help

Seek immediate medical attention for symptoms like uncontrolled bleeding, high fever, severe fatigue, or signs of infection. Regular check-ups are necessary to monitor for relapse, even if symptoms are absent.

Tips for Medical Coders

Document the relapse status clearly, as this code (C92.42) is specific to APL in relapse. Ensure clinical documentation supports the recurrence of the disease, including evidence of prior remission and current active disease. Verify that the PML-RARA fusion gene or related genetic markers are noted if available, as this supports the diagnosis. Avoid coding for remission or active disease without clear documentation of the relapse event.